RT Journal Article
T1 Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria.
A1 Triviño-Ibañez, Eva Maria
A1 Sanchez-Vaño, Raquel
A1 Sopena-Novales, Pablo
A1 Romero-Fabrega, Juan Carlos
A1 Rodriguez-Fernandez, Antonio
A1 Carnero Pardo, Cristobal
A1 Martinez Lozano, Maria Dolores
A1 Gomez-Rio, Manuel
K1 Alzheimer Disease
K1 Humans
K1 Plaque, Amyloid
AB To evaluate the use of amyloid-positron emission tomography (PET) in routine clinical practice, in a selected population with cognitive impairment that meets appropriate use criteria (AUC).A multicenter, observational, prospective case-series study of 211patients from 2 level-3 hospitals who fulfilled clinical AUC for amyloid-PET scan in a naturalistic setting. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability); 1 (low probability); 2 (intermediate probability); 3 (high probability); and 4 (practically sure), before and after amyloid PET. The treatment plan was considered as cognition-specific or noncognition-specific.Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%). Diagnostic prescan confidence according amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate probability (45.7% and 55.1%, respectively). After the amyloid-PET, the diagnostic confidence showed a very different distribution, that was, in the negative-PET group the most frequent categories are very unlikely (70.7%) and unlikely (29.3%), while in the positive-PET group were very probable (57.6%) and practically sure (39%). Only in 14/211 patients (6.6%) the result of the amyloid-PET did not influence the diagnostic confidence, while in 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid-PET results. The therapeutic intention was modified in 93 patients (44.1%). Specific treatment for Alzheimer disease was started, before amyloid-PET, in 80 patients (37.9%).This naturalistic study provides evidence that the implementation of amyloid-PET is associated with a significant improvement in diagnostic confidence and has a high impact on the therapeutic management of patients with mild cognitive impairment fulfilled clinical AUC.
PB Wolters Kluwer Health
YR 2019
FD 2019-06-22
LK http://hdl.handle.net/10668/14290
UL http://hdl.handle.net/10668/14290
LA en
NO Triviño-Ibáñez EM, Sánchez-Vañó R, Sopena-Novales P, Romero-Fábrega JC, Rodríguez-Fernández A, Carnero Pardo C, et al.  Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine (Baltimore). 2019 Jul;98(29):e16509.
DS RISalud
RD Apr 12, 2025